|MDACC Study No:||2009-0651 (clinicaltrials.gov NCT No: NCT01110876)|
|Title:||Phase I / II Adaptive Randomized Trial of Vorinostat, Erlotinib and Temozolomide in Adults with Recurrent Glioblastoma Multiforme|
|Principal Investigator:||John DeGroot|
|Treatment Agent:||Erlotinib; Temozolomide; Vorinostat|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of the combination vorinostat and erlotinib, with or without temozolomide,
that can be given to patients with malignant gliomas. The safety of these drug
combinations will also be studied.